The AP2A1 Knockout HeLa Polyclonal Cells consist of a genetically diverse HeLa cell pool with CRISPR/Cas9-mediated disruption of the AP2A1 gene, enabling loss-of-function studies of the alpha-1 subunit of the AP-2 clathrin adaptor complex. This polyclonal format avoids clonal artifacts and provides a more representative knockout model for heterogeneous cell populations.
The parental HeLa cell line is a human cervical adenocarcinoma model (HPV18-positive) widely used in cancer biology, virology, and cell signaling research. Its epithelial origin, rapid growth, and well-documented genetics make it an ideal host for investigating endocytic and trafficking pathways.
AP2A1 encodes the ??-adaptin A subunit of the heterotetrameric AP-2 complex, which orchestrates clathrin-mediated endocytosis. At the plasma membrane, the AP-2 complex (AP2A1, AP2B1, AP2M1, AP2S1) is recruited by phosphatidylinositol 4,5-bisphosphate (PIP2) and activated by AAK1 phosphorylation. It then engages tyrosine-based sorting motifs on cargo receptors such as EGFR, transferrin receptor (TFRC), and LDL receptor. AP2A1 coordinates clathrin coat assembly via interactions with clathrin heavy chain (CLTC), epsin (EPN1), and EPS15, culminating in dynamin (DNM2)-mediated vesicle scission. This process is critical for receptor internalization, signal desensitization, and nutrient uptake.
In HeLa cells, AP2A1 disruption impairs clathrin-coated pit formation and cargo selection, leading to accumulation of surface receptors and sustained signaling. This model is particularly relevant for studying EGFR trafficking and GPCR internalization via ??-arrestin pathways. Given the HPV18-positive background, AP2A1 loss may also affect viral entry, offering insights into host factors required for pathogen uptake. The polyclonal population enables robust analysis of heterogeneous cellular responses, suitable for high-content imaging and biochemical assays.
Researchers can employ this knockout model to investigate endocytosis in cancer and neurodegeneration, utilizing transferrin uptake assays, EGFR internalization kinetics by flow cytometry, and co-immunoprecipitation of AP-2 complex components (AP2B1, CLTC). Its application extends to drug delivery studies evaluating nanoparticle internalization and to modeling endocytic dysfunction in Alzheimer’s disease. Confirmation of AP2A1 disruption is achievable via Western blotting, RT-qPCR, and immunofluorescence. For further details, contact Ascent Research.
